ICU Medical (NASDAQ:ICUI) Upgraded to Buy at Wall Street Zen

Wall Street Zen upgraded shares of ICU Medical (NASDAQ:ICUI) from a hold rating to a buy rating in a research note released on Monday.

Several other brokerages have also recently commented on ICUI. KeyCorp boosted their target price on shares of ICU Medical from $173.00 to $175.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of ICU Medical in a research note on Wednesday, October 8th. Finally, Piper Sandler boosted their price objective on shares of ICU Medical from $153.00 to $172.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, ICU Medical has a consensus rating of “Moderate Buy” and an average price target of $175.67.

ICU Medical Price Performance

ICU Medical stock opened at $156.17 on Monday. The stock’s fifty day moving average price is $145.71 and its two-hundred day moving average price is $132.26. ICU Medical has a one year low of $107.00 and a one year high of $175.51. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.45 and a quick ratio of 1.19. The firm has a market cap of $3.86 billion, a PE ratio of -503.76 and a beta of 0.80.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.43 by $0.60. ICU Medical had a positive return on equity of 7.71% and a negative net margin of 0.32%.The firm had revenue of $533.30 million during the quarter, compared to the consensus estimate of $511.46 million. During the same period in the prior year, the company posted $1.59 EPS. The company’s revenue was down 8.9% compared to the same quarter last year. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. As a group, research analysts expect that ICU Medical will post 4.11 EPS for the current fiscal year.

Insider Activity at ICU Medical

In other news, Director Elisha W. Finney sold 1,285 shares of the stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $140.42, for a total value of $180,439.70. Following the completion of the transaction, the director directly owned 3,995 shares in the company, valued at approximately $560,977.90. This represents a 24.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Virginia Ruth Sanzone sold 930 shares of the firm’s stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $142.34, for a total value of $132,376.20. Following the sale, the vice president directly owned 5,456 shares in the company, valued at approximately $776,607.04. This trade represents a 14.56% decrease in their position. The SEC filing for this sale provides additional information. 1.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ICU Medical

Large investors have recently bought and sold shares of the company. SG Americas Securities LLC grew its holdings in shares of ICU Medical by 76.3% during the fourth quarter. SG Americas Securities LLC now owns 4,065 shares of the medical instruments supplier’s stock worth $580,000 after purchasing an additional 1,759 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in ICU Medical in the 4th quarter valued at approximately $745,000. Wealth Enhancement Advisory Services LLC acquired a new stake in ICU Medical during the 4th quarter worth approximately $392,000. CIBC Bancorp USA Inc. bought a new stake in ICU Medical during the 3rd quarter worth approximately $309,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in ICU Medical in the 3rd quarter valued at approximately $304,000. 96.10% of the stock is currently owned by institutional investors.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.